IDegAsp was superior in lowering fasting plasma glucose ( FPG ) ( ETD -1.06 mmol/L , 95 % CI -1.43 ; -0.70 , p < 0.001 ) , and resulted in a lower final mean daily insulin dose ( 0.79 U/kg vs 0.99 U/kg , estimated rate ratio [ RR ] 0.79 , 95 % CI 0.73 ; 0.85 , p < 0.0001 ) .